Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants

Publication: Clin Pharmacokinet
Software: GastroPlus®


Physiologically based pharmacokinetic (PBPK) modelling can assist in the development of drug therapies and regimens suitable for challenging patient populations such as very young children. This study describes a strategy employing PBPK models to investigate the intravenous use of the neuraminidase inhibitor oseltamivir in infants and neonates with influenza.